menu
    • menu
    [{"orgOrder":0,"company":"Gabrail Cancer Center Research","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Human Papillomavirus 9-valent Vaccine, Recombinant","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Gabrail Cancer Center Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Liquid Suspension","sponsorNew":"Gabrail Cancer Center Research \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Gabrail Cancer Center Research \/ Merck & Co"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Mylan Group","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Partnership","leadProduct":"Lorazepam","moa":"||GABA A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Mylan Group","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Mylan Group"},{"orgOrder":0,"company":"Children\u2019s Hospital Los Angeles","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Controlled Substance","year":"2023","type":"Funding","leadProduct":"Lorazepam","moa":"||GABA A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Children\u2019s Hospital Los Angeles","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children\u2019s Hospital Los Angeles \/ National Institutes of Health","highestDevelopmentStatusID":"15","companyTruncated":"Children\u2019s Hospital Los Angeles \/ National Institutes of Health"},{"orgOrder":0,"company":"Sequential Medicine Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Diphenhydramine","moa":"||Histamine H1 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Sequential Medicine Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sequential Medicine Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sequential Medicine Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Lorazepam","moa":"||GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Phase I","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Northwell Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Northwell Health \/ Inapplicable"},{"orgOrder":0,"company":"University of Twente","sponsor":"H\u00f4pital Universitaire de Bruxelles | ZonMw | Belgium Health Care Knowledge Centre","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Lorazepam","moa":"||GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Undisclosed","graph3":"University of Twente","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Twente \/ H\u00f4pital Universitaire de Bruxelles | ZonMw | Belgium Health Care Knowledge Centre","highestDevelopmentStatusID":"1","companyTruncated":"University of Twente \/ H\u00f4pital Universitaire de Bruxelles | ZonMw | Belgium Health Care Knowledge Centre"}]

    Find Clinical Drug Pipeline Developments & Deals for Temesta

    Menu

    Temesta

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Pfizer Inc

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Pfizer Inc

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lorazepam,Inapplicable

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved FDF

                            Sponsor : Mylan Group

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Pfizer Partners with Mylan for Marketing of Ativan and Pacitane

                            Details : The partnership aims for the marketing and sale of two of pfizer's brands, Ativan (lorazepam) to treat anxiety disorders and Pacitane to treat Parkinson's disease.

                            Product Name : Ativan

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            February 24, 2025

                            Lead Product(s) : Lorazepam,Inapplicable

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved FDF

                            Sponsor : Mylan Group

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Gabrail Cancer Center Research

                            Country arrow
                            EPSC
                            Not Confirmed

                            Gabrail Cancer Center Research

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Papillomavirus 9-valent Vaccine, Recombinant,Lidocaine,Lorazepam

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HPV Vaccine Reduced Dose

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            January 29, 2025

                            Lead Product(s) : Human Papillomavirus 9-valent Vaccine, Recombinant,Lidocaine,Lorazepam

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            University of Twente

                            Country arrow
                            EPSC
                            Not Confirmed

                            University of Twente

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lorazepam,Midazolam,Diazepam,Levetiracetam,Divalproex Sodium,Lacosamide

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Hôpital Universitaire de Bruxelles | ZonMw | Belgium Health Care Knowledge Centre

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation-2 (TELSTAR-2)

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            August 12, 2024

                            Lead Product(s) : Lorazepam,Midazolam,Diazepam,Levetiracetam,Divalproex Sodium,Lacosamide

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Hôpital Universitaire de Bruxelles | ZonMw | Belgium Health Care Knowledge Centre

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Children’s Hospital Los Angeles

                            Country arrow
                            EPSC
                            Not Confirmed

                            Children’s Hospital Los Angeles

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lorazepam,Tofacitinib Citrate

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : National Institutes of Health

                            Deal Size : $5.3 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Children’s Hospital Los Angeles to Launch $5.3 Million NIH Study for First Clinical Trial for Down Syndrome ...

                            Details : The funding will be used in the randomized controlled trial which will investigate the safety and effectiveness of three different treatments for Down syndrome regression disorder. Lorazepam is an anti-anxiety medication that treats catatonia and other s...

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            January 25, 2023

                            Lead Product(s) : Lorazepam,Tofacitinib Citrate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : National Institutes of Health

                            Deal Size : $5.3 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Northwell Health

                            Country arrow
                            EPSC
                            Not Confirmed

                            Northwell Health

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lorazepam,Inapplicable

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lorazepam Effects on Neuroimaging Measures

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            December 17, 2020

                            Lead Product(s) : Lorazepam,Inapplicable

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Sequential Medicine Ltd

                            Country arrow
                            EPSC
                            Not Confirmed

                            Sequential Medicine Ltd

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Diphenhydramine,Zolpidem Tartrate,Lorazepam

                            Therapeutic Area : Sleep

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SM-1 vs. an Active Comparator in A Model of Transient Insomnia

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 20, 2020

                            Lead Product(s) : Diphenhydramine,Zolpidem Tartrate,Lorazepam

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            OSF Healthcare System

                            Country arrow
                            EPSC
                            Not Confirmed

                            OSF Healthcare System

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Phenobarbital,Lorazepam

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phenobarbital vs Ativan for Alcohol Withdrawal in the Intensive Care Unit

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 07, 2019

                            Lead Product(s) : Phenobarbital,Lorazepam

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Sequential Medicine Ltd

                            Country arrow
                            EPSC
                            Not Confirmed

                            Sequential Medicine Ltd

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Diphenhydramine,Zolpidem Tartrate,Lorazepam

                            Therapeutic Area : Sleep

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Investigational Study to Assess Efficacy and Pattern of Use of SM-1 in Subjects With a History of Transient...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 09, 2017

                            Lead Product(s) : Diphenhydramine,Zolpidem Tartrate,Lorazepam

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Sequential Medicine Ltd

                            Country arrow
                            EPSC
                            Not Confirmed

                            Sequential Medicine Ltd

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Diphenhydramine,Zolpidem Tartrate,Lorazepam

                            Therapeutic Area : Sleep

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SM-1 vs 2 Comparators and Placebo in Participants With a History of Transient Insomnia.

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 06, 2017

                            Lead Product(s) : Diphenhydramine,Zolpidem Tartrate,Lorazepam

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Sequential Medicine Ltd

                            Country arrow
                            EPSC
                            Not Confirmed

                            Sequential Medicine Ltd

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Diphenhydramine,Zolpidem Tartrate,Lorazepam

                            Therapeutic Area : Sleep

                            Study Phase : Phase II

                            Sponsor : Clinilabs

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pilot Study of a Combination Drug Product for Treatment of Short-term Insomnia

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 02, 2016

                            Lead Product(s) : Diphenhydramine,Zolpidem Tartrate,Lorazepam

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase II

                            Sponsor : Clinilabs

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth